Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autoimmune disease

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Mtech Access

- PMLiVE

Sanofi’s Rezurock fast-tracked by NHS for rare chronic graft versus host disease

Around 400 stem cell or bone marrow transplant patients will develop the condition each year in England

- PMLiVE

UKRI appoints iiCON to deliver £1.5m initiative to tackle infection transmission

The project will aim to accelerate solutions that leverage technologies such as AI and novel diagnostics

- PMLiVE

Sanofi presents positive results for rilzabrutinib in chronic spontaneous urticaria

Phase 3 development of the treatment is expected to commence later this year

- PMLiVE

AbbVie and Tentarix partner to develop oncology and immunology biologics

The collaboration will use Tentarix's proprietary platform to develop biologics against two targets

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing forms of MS

Results from a mid-stage of the candidate were recently published in the NEJM

- PMLiVE

Sanofi presents positive results for Pompe disease enzyme replacement therapy

The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK

- PMLiVE

Academics and industry collaborate to advance precision therapy in breast cancer

The AI-based clinical study is funded by a grant worth almost £800,000 from Innovate UK

- PMLiVE

UKRI announces £80m investment into new UK research hubs for AI research

The nine hubs will help to evolve AI across applications, including healthcare treatments

- PMLiVE

Study finds doctors have difficulty diagnosing disease in images of darker skin

Researchers have found that AI could be used to more accurately diagnose these patients

- PMLiVE

Almirall and Microsoft partner to accelerate digital transformation in medical dermatology

The alliance is aimed at advancing the research of solutions for dermatological diseases

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by FDA for younger eosinophilic oesophagitis patients

Around 21,000 children aged under 12 years in the US are being treated for the inflammatory disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links